We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Gene Panel Predicts Damage in Donated Kidneys

By LabMedica International staff writers
Posted on 04 Aug 2016
Print article
Image: The Aperio Scanscope CS whole slide scanner system (Photo courtesy of Leica).
Image: The Aperio Scanscope CS whole slide scanner system (Photo courtesy of Leica).
Kidney transplantation is a life-extending procedure and a panel of genes has been identified that can help predict whether a transplanted kidney will later develop fibrosis, an injury which can cause the organ to fail.

Chronic allograft damage, or interstitial fibrosis and tubular atrophy of unknown cause, is the major cause of allograft loss in the first year after transplantation. Clinical and histological events associated with interstitial fibrosis and tubular atrophy are poorly predictive of allograft loss, making it difficult to identify allografts that could benefit from early interventions to prevent progression of fibrosis.

A multicenter team of scientists led by those at the Icahn School of Medicine at Mount Sinai (New York, NY, USA) prospectively collected biopsies from 204 renal allograft recipients with stable renal function three months after transplantation. They used microarray analysis to investigate gene expression in 159 of these tissue samples. Their aim was to genes that correlated with the Chronic Allograft Damage Index (CADI) score at 12 months, but not fibrosis at the time of the biopsy. The CADI score is a measure of the level of fibrosis in the transplanted kidney.

Two tissue cores were taken from each of the three-month and one year protocol renal biopsies of the Genomics of Chronic Allograft Rejection (GoCAR) cohort. One core was processed for histology and the other core was processed for messenger ribonucleic acid (mRNA). Immunohistochemistry was done on an automated stainer on paraffin sections stained with a rabbit polyclonal antibody (American Research Products, Inc, Waltham, MA, USA). All slides were scanned with an Aperio CS whole slide scanner (Leica, Wetzlar, Germany) and high-resolution digital images and archived in an image database. Total RNA was extracted from percutaneous graft biopsy samples, processed onto gene chips and scanned using GeneChip Scanner 7G (Affymetrix Inc, Santa Clara, CA, USA).

The investigators identified a set of 13 genes that was independently predictive for the development of fibrosis at one year. The routine pathological variables were unable to identify which histologically normal allografts would progress to fibrosis whereas the predictive gene set accurately discriminated between transplants at high and low risk of progression. The rate of correlation of the identified gene set with damage was greater than the clinico-pathological variables currently used in practice to identify kidney transplant recipients at risk of allograft damage and loss.

Barbara Murphy, MD, the study leader, said, “By helping us better understand the causes of damage to transplanted kidneys; this study has the potential to change how we monitor and manage all renal transplant patients. The study offers the potential to identify renal transplant recipients at risk for a loss of the new organ prior to the development of irreversible damage. This would mean that doctors might eventually have the opportunity to change the therapeutic treatment approach in order to prevent fibrosis from progressing at all.” The study was published on July 22, 2016, in the journal The Lancet.

Related Links:
Icahn School of Medicine at Mount Sinai
American Research Products
Leica
Affymetrix
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.